Hematologic Oncology Update Multiple Myeloma — Fourth Annual National General Medical Oncology Summit
May 31, 2025
In this engaging discussion, Dr. Natalie Callender and Dr. Tom Martin, renowned experts in hematologic oncology, tackle the intricacies of multiple myeloma treatment. They delve into unique challenges for elderly patients, highlighting key findings from the AQUILA trial that enhance treatment strategies. The episode also explores the promising role of Selenexer and advances in CAR T-cell therapies, bringing light to the complexities of neurotoxicity and emerging therapies. The conversation emphasizes personalized treatment approaches for better outcomes in diverse patient demographics.
AI Snips
Chapters
Transcript
Episode notes
Elderly Myeloma Treatment Advice
- Use daratumumab and lenalidomide with dose reductions for elderly multiple myeloma patients with comorbidities.
- Avoid quadruplet therapy in very elderly patients to minimize toxicity risks.
Steroid Use in Elderly Patients
- Limit dexamethasone doses to 20 mg for patients over 70 to reduce cognitive side effects.
- Remove dexamethasone entirely after initial daratumumab doses for better tolerance.
Early Treatment Benefits Smoldering Myeloma
- Early treatment of high-risk smoldering myeloma with single-agent daratumumab significantly improves progression-free and overall survival.
- This challenges the traditional observation-only approach for smoldering myeloma patients.